2024
Estimates of intra-cluster correlation coefficients from 2018 USA Medicare data to inform the design of cluster randomized trials in Alzheimer’s and related dementias
Ouyang Y, Li F, Li X, Bynum J, Mor V, Taljaard M. Estimates of intra-cluster correlation coefficients from 2018 USA Medicare data to inform the design of cluster randomized trials in Alzheimer’s and related dementias. Trials 2024, 25: 732. PMID: 39478608, PMCID: PMC11523597, DOI: 10.1186/s13063-024-08404-2.Peer-Reviewed Original ResearchConceptsIntra-cluster correlation coefficientIntra-cluster correlation coefficient estimationSample size calculationED visitsMedicare dataMedicare fee-for-service beneficiariesEmergency departmentFee-for-service beneficiariesSize calculationDiagnosis of ADRDNational Medicare dataCluster randomized trialHospital referral regionsHospital service areasHealth care systemBackgroundCluster randomized trialsPopulation-level dataRandomized trialsDesign of cluster randomized trialsEvaluate interventionsReferral regionsCare systemICC estimatesADRDCorrelation coefficient
2023
Sample size requirements for testing treatment effect heterogeneity in cluster randomized trials with binary outcomes
Maleyeff L, Wang R, Haneuse S, Li F. Sample size requirements for testing treatment effect heterogeneity in cluster randomized trials with binary outcomes. Statistics In Medicine 2023, 42: 5054-5083. PMID: 37974475, PMCID: PMC10659142, DOI: 10.1002/sim.9901.Peer-Reviewed Original ResearchConceptsSample size proceduresSize proceduresEfficient Monte Carlo approachTreatment effect heterogeneitySample size methodsMonte Carlo approachContinuous effect modifiersBinary outcomesEffect heterogeneityCarlo approachNumerical illustrationsNecessary sample sizeGeneralized linear mixed modelLinear mixed modelsPopular classSample size requirementsStatistical powerAverage treatment effectHeterogeneous treatment effectsSample size calculationMixed modelsSize methodSize calculationSize requirementsCluster Randomized Trial
2021
Methodological challenges in pragmatic trials in Alzheimer’s disease and related dementias: Opportunities for improvement
Taljaard M, Li F, Qin B, Cui C, Zhang L, Nicholls SG, Carroll K, Mitchell SL. Methodological challenges in pragmatic trials in Alzheimer’s disease and related dementias: Opportunities for improvement. Clinical Trials 2021, 19: 86-96. PMID: 34841910, PMCID: PMC8847324, DOI: 10.1177/17407745211046672.Peer-Reviewed Original ResearchConceptsPragmatic trialAlzheimer's diseasePrimary outcomeSample size calculationGroup treatment trialsPairs of reviewersDementia researchSize calculationCluster Randomized TrialGroup treatment designRandomized trialsTreatment trialsIntracluster correlationMethodological qualityTrial reportsBaseline assessmentDiseaseTrialsDementiaKey methodological characteristicsOutcomesType IMethodological quality indicatorsUnique methodological challengesSame individual